Senti Biosciences, Inc.
Senti Biosciences, Inc. (SNTI): 2 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E 13.91 · 0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for Senti Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$29.6M
Cash
$12.5M
Quarterly Burn
$7.5M
Runway
5.3 mo
Revenue
$16K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Senti Biosciences, Inc.'s pipeline?
Senti Biosciences, Inc. (SNTI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Senti Biosciences, Inc.'s lead drug candidate?
Senti Biosciences, Inc.'s most advanced tracked candidate is senti-202 (Phase 1) for AML/MDS.
What is Senti Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Senti Biosciences, Inc. has approximately 5.3 months of cash runway.
What is Senti Biosciences, Inc.'s market capitalization?
Senti Biosciences, Inc.'s market capitalization is approximately $29.6M.
Who is the CEO of Senti Biosciences, Inc.?
Dr. Timothy K. Lu M.D., Ph.D. is the chief executive officer of Senti Biosciences, Inc. (SNTI).
Get the full picture on Senti Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.